Influenza

>

Latest News

Osivax Launches Phase 2b Study of OVX836 for Influenza A
Osivax Launches Phase 2b Study of OVX836 for Influenza A

October 1st 2025

Multicenter study will measure efficacy, safety, and immunogenicity in adults 18–59 across Europe.

2024 to 2025 US Influenza Season Sets Record Hospitalization Rate
2024 to 2025 US Influenza Season Sets Record Hospitalization Rate

September 12th 2025

Technology Demonstrates Ability to Transform Influenza Vaccines Into Universal Formulations
Technology Demonstrates Ability to Transform Influenza Vaccines Into Universal Formulations

September 10th 2025

High-Dose Influenza Vaccine vs Standard Dose: Hospitalization Outcomes in Older Adults
High-Dose Influenza Vaccine vs Standard Dose: Hospitalization Outcomes in Older Adults

August 30th 2025

 RFK, HHS OKs Removal of Thimerosal From Influenza Vaccines
RFK, HHS OKs Removal of Thimerosal From Influenza Vaccines

July 24th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.